UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$950M |
| 2 |
Linde
LIN
|
+$886M |
| 3 |
Amgen
AMGN
|
+$812M |
| 4 |
Pinduoduo
PDD
|
+$400M |
| 5 |
Advanced Micro Devices
AMD
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ametek
AME
|
+$475M |
| 2 |
Microsoft
MSFT
|
+$266M |
| 3 |
Amazon
AMZN
|
+$221M |
| 4 |
VMW
VMware, Inc
VMW
|
+$197M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$140M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.09% |
| 2 | Healthcare | 14.47% |
| 3 | Financials | 11.11% |
| 4 | Consumer Discretionary | 10.49% |
| 5 | Industrials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Heron Therapeutics
HRTX
$92.9M
| $167K | ﹤0.01% |
110,752
| – | – |
|
|
BASE
2527
DELISTED
Couchbase
BASE
| $166K | ﹤0.01% |
11,827
| – | – |
|
2528
Pulmonx
LUNG
$87.6M
| $166K | ﹤0.01% |
+14,847
| New | +$147K |
|
2529
EverCommerce
EVCM
$1.93B
| $166K | ﹤0.01% |
+15,649
| New | +$151K |
|
2530
Marcus Corp
MCS
$945M
| $164K | ﹤0.01% |
+10,225
| New | +$157K |
|
2531
El Pollo Loco
LOCO
$462M
| $163K | ﹤0.01% |
16,967
+3,905
| +30% | +$44.5K |
|
|
OLPX
2532
DELISTED
Olaplex Holdings
OLPX
| $160K | ﹤0.01% |
37,515
-87,500
| -70% | -$466K |
|
|
EBIX
2533
DELISTED
Ebix Inc
EBIX
| $160K | ﹤0.01% |
12,095
-3,576
| -23% | -$62.2K |
|
2534
Babcock & Wilcox
BW
$1.39B
| $157K | ﹤0.01% |
25,922
+14,459
| +126% | +$89.2K |
|
2535
Taboola.com
TBLA
$1.11B
| $157K | ﹤0.01% |
57,700
| – | – |
|
|
ILPT
2536
Industrial Logistics Properties Trust
ILPT
$586M
| $155K | ﹤0.01% |
50,367
-86,333
| -63% | -$337K |
|
2537
Workhorse Group
WKHS
$36.3M
| $154K | ﹤0.01% |
39
-38
| -49% | -$210K |
|
2538
Dream Finders Homes
DFH
$1.36B
| $152K | ﹤0.01% |
11,457
| – | – |
|
2539
GoodRx Holdings
GDRX
$1.26B
| $147K | ﹤0.01% |
23,477
+971
| +4% | +$5.41K |
|
2540
Nektar Therapeutics
NKTR
$2.58B
| $147K | ﹤0.01% |
13,911
+2,766
| +25% | +$83.7K |
|
2541
Ivanhoe Electric
IE
$1.74B
| $146K | ﹤0.01% |
+12,000
| New | +$161K |
|
2542
Veru
VERU
$37.4M
| $145K | ﹤0.01% |
12,467
+4,392
| +54% | +$178K |
|
2543
Enel Chile
ENIC
$6.28B
| $143K | ﹤0.01% |
53,122
| – | – |
|
2544
Dyne Therapeutics
DYN
$4.9B
| $141K | ﹤0.01% |
12,222
| – | – |
|
|
MMAT
2545
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $139K | ﹤0.01% |
3,415
| – | – |
|
2546
Senseonics Holdings Inc
SENS
$366M
| $139K | ﹤0.01% |
9,754
-10,813
| -53% | -$217K |
|
2547
MiMedx Group
MDXG
$633M
| $137K | ﹤0.01% |
+40,062
| New | +$155K |
|
|
PNT
2548
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $135K | ﹤0.01% |
18,538
-18,200
| -50% | -$135K |
|
2549
TETRA Technologies
TTI
$1.26B
| $133K | ﹤0.01% |
50,180
+30,066
| +149% | +$105K |
|
2550
Tango Therapeutics
TNGX
$4.41B
| $130K | ﹤0.01% |
32,997
+20,797
| +170% | +$121K |
|
Similar funds
UBS AM's Q1 2023 Portfolio in Review
As of Q1 2023, UBS AM held 2,762 positions worth $206B, up 8.3% from $191B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
UBS AM's Q1 2023 filing shows 231 new, 1,328 increased, 856 reduced and 85 closed positions. Its largest new stake was Amgen: 3,308,425 shares worth $800M. The largest sale was Ametek, an estimated $475M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
- UBS AM's largest Q1 2023 buy was Amgen: 3,308,425 shares worth $800M.
- UBS AM added most to Abbott in Q1 2023, an estimated $950M increase.
- UBS AM's biggest Q1 2023 reduction was Ametek, cutting an estimated $475M.
- UBS AM fully exited SVB Financial Group in Q1 2023, selling an estimated $77.3M.
- UBS AM's ten largest holdings make up 22% of its $206B portfolio in Q1 2023.
- UBS AM opened 231 new positions and closed 85 in Q1 2023.
- UBS AM's portfolio value rose 8.3% quarter-over-quarter to $206B.
Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.